DYOR - - - - - - - - - Biom Technologies mid-July 2010 AIM
This is the new resting place for Stanelco, the wonder producer of starch-based food-trays...only they didn't catch on.Over the last 10 years to 2010 the 0.1p shares traded abour 2.5p then shot up to 24p during 2005 with promise of Tray-Trials I understand. Within a year or so, they fell to new depths and finished at 0.2p Of course they were full-list then and some were held in ISA's hoping there would be a big profit...only now these are distressed sales as the Company slunk off to AIM, presumably "...to provide better shareholder-value"
Perhaps someone closer to the Co. can explain why the new name is Biome
....rhymes with Home. Often it is done to remove the previous sp-history.
Could it be..so new investors can bask in ignorance, etc. I'm not aware of any "change" in fortune for SEO, rather the reverse.
In my limited experience, the longer the name of a company the longer you have to wait for any return...Huh . . . . . .
. SEO had been a terrible investment.
DYOR.
Can Biome be any worse...?
EDIT ( 24April2017)- "just woken up" -me not BIOME - sp is 154, but I note about June 2013 there was what looks like a CONsolidation . . do I recall many LT investors were sold-short?... as I believe the (new share) numbers were terrible! . . . Anyone?

Finally sold, so completely out.
I wish all those still in the best of luck, as I get no pleasure from seeing any investor screwed.

Bad luck Greek but as you say, at least you can offset against gains.

BB, I had hoped that BIOM would announce that the increased expenditure was due to a strategic investment in the purchase of thousands of 1st class stamps!

Blimey greek bit extreme, if you were that short of a postage stamp I'd have lent you one.,.

Thanks Balerboy,

But with BIOME shares, could you afford to post it to me!

Regards to all, as probably won't post on here again, some no doubt thinking, 'Thank goodness for that!

RNS Number : 4649E

Biome Technologies PLC

31 May 2012

Biome Technologies plc ("Biome", "the Company" or "the Group")

Trading Update

In the trading statement released by Biome on 25 April, it was stated that revenues were slower to achieve than expected in the first quarter, particularly in the Bioplastics Division. Unfortunately, sales within this division have been markedly below our expectation during April and May. The Board now believes that this will have a significant adverse impact on the Group results for the full year; this will be particularly felt in the first half. The RF Division is trading in line with the Board's expectations and its order pipeline remains strong.

Customers of the Group's Bioplastics Division are reporting subdued demand for their own bioplastic end products, particularly in the markets of southern Europe. During 2011, the Italian market for bioplastics became one of the largest in Europe following the implementation of regulations (first introduced in early 2011 and reaffirmed in early 2012) mandating the use of biodegradable products for shopping bags. However, in the early part of May this year Biome became aware that the financial penalty for non-compliance with these regulations would now be deferred until the end of 2013. This has resulted in the recent and significant change in the adoption rate in the Italian market and a broader disruption to the supply and demand balance of bioplastics in Europe. In the current, year the Board expects its joint venture company, Biotec, to be the most adversely affected part of the Group.

The impact of these changes to the dynamics of the bioplastics' market will result in it taking longer than previously anticipated for the Group to reach profitability. The Group's cash balance as at the end of April was GBP1.4m. However, this would have reduced significantly as the year progressed unless action is taken to reduce costs. As a result, the Board is taking steps to reduce cash costs by approximately GBP600k per year. This will better preserve Biome's ability to reach profitability and protect its business model.

Whilst the above developments, which affect the fast development of Biome's bio-plastics market, are disappointing, the Board believes firmly that they constitute a pause in a fast-developing market rather than an indication of anything more fundamental.

Biome continues to progress successfully with new products and technologies to improve its future prospects and develop new markets. The RF Division is performing well and remains a cash generator for the group as a whole. The Durapipe project remains on track and is successfully passing agreed milestones with our partner. The new technology for heat and cold resistant bio-plastic materials continues to gain positive reaction from product tests with prospective customers. The Board expects these new developments to make contributions to turnover in 2013.

-Ends-

You have to wonder if this is the end, delisting from AIM will no doubt save the company money in the long run.

38% fall in sp . . it seems the bag of potato bits was eaten by the nightwatch staff and no-one dared tell them.
This investment is a joke . . . . are they run by monkies.
A company selling Jubilee flags would make better returns.
EDIT (12July2012)_I see a murmer of excitement as the Euro Court issue looks like it might be over - but that should be TINY news compared with their sales efforts - pathetic, IMHO. There's still time to sell Flags . . . if SportGB wins anything.

A bit of nostalgia


http://www.moneyam.com/InvestorsRoom/posts.php?tid=7681#lastread

Up the creek with othout a paddle I am afraid for me, just another one - hey ho!!!! I don't know about jubilee flags they would have done better selling sand to arabs.

9 June 2012

Biome Technologies plc ("Biome", "the Company" or "the Group")
Loan Facility Extension/Directorate Change


Biome Technologies plc is pleased to announce it has concluded an extension of its secured debt facility with Fortis Commercial Finance. The facility, first put in place in May 2011, provides access to additional working capital funding for the Company's subsidiary, Biome Bioplastics, to support its growth. This facility has now been extended to May 2014 and its quantum of up to £2m is governed by various attributes of the debtor balance of Biome Bioplastics. The facility remains unused at present.

Further to measures outlined in its recent Trading Update to reduce cash costs, the Company announces that Declan Brown, Group Finance Director, will be leaving employment with the Company on or before 30th November 2012 to pursue other opportunities. Declan will remain on the Board while his employment continues. At the end of Declan's term of office, the Company's accounting and financial management requirements will be provided on a part-time interim basis by Michael Kayser FCMA, in conjunction with the Group's Financial Controller. Michael is an existing non-executive of the Company and is Chair of the Group's Audit and Remuneration Committees. His previous experience includes roles as Group Finance Director at Laporte PLC for five years and Finance Director of Guinness Brewing Worldwide.

John Standen, Chairman, said: "The Board would like to thank Declan for his support and contribution during his time with us and wish him well for the future."

Further, in accordance with AIM Rule 20, the Company's Annual Report for the year ended 31 December 2011 is available for download on its website (www.biometechnologiesplc.com).

-Ends-

Patent Litigation Update

Biome is pleased to announce significant positive developments in the patent litigation cases currently being heard against its joint venture company, Biotec.

Biome first announced on 29 May 2007 that it was evaluating claims against Biotec, by Novamont S.p.A ("Novamont"), an Italian competitor. Subsequent updates have clarified that Novamont had brought proceedings in the French and Italian courts against Biotec and SPhere, France (Biome's joint venture partner in Biotec), claiming infringement of the French and Italian designations of a number of Novamont's patents (EP'505, EP'559 and EP'120) by the products that are or have been manufactured and sold by Biotec.

The result of the case being conducted in the Turin court was received by the Company on 10 July 2012. The Board is pleased to report that the court in the first instance has found in favour of Biotec and has revoked the Italian designations of Novamont's patents EP 505, EP '559 (with the exception of claim 12, however this also was found not to be infringed), and EP '120 (claims 21 and 22). This is the first formal finding in the Italian jurisdiction and represents a very encouraging development in this multi-jurisdictional process. Appeal paths are available for these findings in Turin and a parallel case in Milan remains ongoing.

Over the past eighteen months, Biome and its joint venture partner, SPhere, have sought to emphasise the broader validity of Biotec's position in Europe. Following proceedings, SPhere received two German first instance court judgements that the German designation of Novamont's patent EP '559 and EP '120 are invalid in this territory. Subsequently, Novamont has appealed the EP '559 decision. Biotec also engaged in a similar process to demonstrate that the German designation of Novamont's patent EP '505 was invalid in Germany, prior to its expiry in January 2009. In the context of this process, Novamont declared in a legally binding way to the German Federal Patent Court that it will refrain from enforcing the German designation of its patent EP'505 against Biotec in Germany as well as to refrain from claiming any damages from Biotec in connection with the German designation of patent EP '505. Consequently Biotec has withdrawn this invalidity case.

It has been noted before that the first court judgment on this litigation was received in France in April 2010 and was in favour of Biotec and SPhere in that no proof of infringement was found for all three Novamont patents (above) and certain claims of EP '120 were found to be invalid. Various appeal paths in the French court were available to all parties and earlier this year Biotec and SPhere lodged an appeal against the remaining validity of Novamont's patents EP'559 and EP'505 in France. Subsequently, Novamont has appealed the complete French court decision.

Biome and Biotec continue to take professional and technical advice with regard to this litigation. The Board has sought and will continue to seek complete resolution of this matter as soon as it is feasible.

-Ends-

17 July 2012

Biome Technologies plc ("Biome", "the Company" or "the Group")

Financing and loan repayment

Biome Technologies plc announces that it has received EUR255,000 in repayment and accrued interest on its shareholder loans with Biotec, its joint venture manufacturing facility in Germany. Sphere S.A., Biome's partner in the joint venture, has received a similar payment in relation to its interest in Biotec.

In addition, Biotec entered into a EUR1.5m loan agreement with Sparkasse Emmerich last week. This loan has a five year term, carries a fixed interest rate of 3.25% and is secured against Biotec's property. Repayments of 15% of the principal amount fall due at the end of each of the first four years with the remaining 40% due at the end of year five.

Paul Mines, Chief Executive of Biome Technologies, said:

"The Board is pleased to see the second interest and loan payment on the loans from its jointly owned manufacturing facility. Biotec's loan from Sparkasse bank underpins the working capital requirements of the joint venture business and supports the Company's strategy of securing a sustainable business in the bioplastics market."

-Ends-

Interim Management Statement

Total Group revenues achieved in the first half of 2012 were £7.5m, down 28% on the same period in 2011. In the Trading Update of 31 May, it was stated that sales within the Bioplastics Division for April and May were markedly below our expectations following legislative changes in Italy and wider disruption to the supply and demand balance in Europe. This is reflected in the second quarter, with Group revenues of £2.9m (Q2 2011: £4.9m), 38% below the revenues of £4.6m achieved in the first quarter.

The Bioplastics Division saw revenues drop from £4.3m in Q1 to £2.2m in the second quarter (Q2 2011: £3.9m). Within this, Biotec was most adversely affected with revenues down 58% from £3.0m in Q1 to £1.2m in the second quarter (Q2 2011: £1.8m) as third-party sales were depressed due to the previously reported demand changes in southern Europe. In Biome Bioplastics, revenues were down a more modest 26% to £1.0m in the second quarter compared to £1.3m in Q1 (Q2 2011: £2.2m) with some evidence that the broader application base and geographic diversity is providing greater resilience to the current turbulence in the market.

The Stanelco RF Technologies Division continues to perform as expected with revenues of £0.7m in Q2, up 95% compared to the first quarter (Q2 2011: £0.9m). The pipeline for fibre optic furnace systems and associated spares continues to grow; orders for nine units to the value of £1.2m have been received and are under build for the second half, with further orders pending. Diversification into new industrial markets continues and the Durapipe UK project is progressing well with the first prototype unit expected to be delivered shortly.

The Group's cash position at 30 June 2012 was £1.1m (30 April 2012: £1.5m). Following the period end, the Group announced that Biotec had entered into a €1.5m loan agreement with Sparkasse Emmerich and that €255k in repayment and interest had been repaid to Biome under the shareholder agreement. The Group's secured debt facility of up to £2m with Fortis Commercial Finance remains available but is currently not utilised.

The Board continues to believe that these market developments constitute a pause in a fast developing market and that the drivers of requirements for biodegradable and bio-based materials will grow with time.

With respect to the patent litigation, updated on 12 July, the recent positive findings in the Court of Turin in the context of other court findings provide further confidence in the value and potential of the Group's technology Biome is well placed and continues to expedite new product development with a focus on those opportunities likely to yield growth in the shorter term. Actions to reduce costs by around by £0.6m on an annualised basis have now been completed and the benefits will build in the second half. The Group is trading in-line with the Board's revised expectations.

-Ends-

Revenue down even more.

And yet they say, 'Biome Technologies plc, the bioplastics and RF technology business, is pleased to announce '.
I know its the usual used jargon, but I would have thought that, ''Biome Technologies plc, the bioplastics and RF technology business, is ASHAMED to announce ', would be more apt.

Still they have yet another loan facility arranged, I wonder at what interest!.

Can this company become any more pathetic.
Surely the end must be near!

Greek - I should have ended the post with "blah blah blah" - underwhelming statement as always!

Hi Skinny,

Agreed.
I also like this bit, 'The Group is trading in-line with the Board's revised expectations'.

Which means, 'We thought it would be c**p and we were right'.

Bonuses all round!.

Your learning Greek....haha

But will the shareholders ever learn, (it took me far too long).
With a 20% drop and a 22% spread, who in their right mind would buy these!

I have long thought that the RF side of the business is where they should be trading and that they should sell the bioplastics division. Biome has too much competition in bioplastics and is too small to carve out and decent market share. The management however are a complete joke, I'd favour a punt on a 500:1 horse with three legs and half a tail running the national over this board.

http://plasticsnews.com/headlines2.html?id=26071

McDonald's using compostable plastics at the London Olympics
By Anthony Clark | PRW
Posted July 26, 2012
LONDON (July 26, 7 a.m. ET) -- McDonald’s, which will be running the world's largest fast-food outlet at the Olympic park in Stratford, east London, will be using Novamont’s Mater-Bi bioplastic for its cups, cutlery, straws, lids and containers.

“Many McDonald’s items were already compliant with the EN13432 compostability standards but did not have the certification,” said the company’s environment consultant Helen McFarlane.

“We obtained this by working alongside our suppliers for almost two years, with considerable investment in research and development.”

Mater-Bi will compost with anaerobic digestion, according to Italy’s Novamont, helping make the expected 3,300 metric tons of food and food-related packaging waste that the games will generate easier to handle than if conventional materials are used.

London Olympic and Paralympic Games organizing committee (Locog) has set the objective of 70 percent of the waste produced by the events should go for recycling, re-use or composting.

Novamont operates in the UK, Germany, France, Benelux, Scandinavia, Denmark, US, China, Japan, Australia and New Zealand.